With over 40 years of experience, Dr. Charles E. Day began his medical career with a Doctor of Philosophy, summa cum laude, in biochemistry and organic chemistry from the University of Louisville in 1970.

He then became a research scientist for the Upjohn Company with the responsibility of discovering new drugs for preventing atherosclerosis, lowering plasma cholesterol and modulating plasma lipoprotein concentrations. In 1976 he became the research project leader, supervising a team of 10 research scientists and assistants responsible for preclinical development of new drugs for atherosclerosis, cholesterol reduction, lipoprotein modulation and obesity.

In 1985, Dr. Day left the Upjohn Company to become the CEO and Director of Research for Audax, Inc., in Leitchfield, KY. He remains responsible for all scientific and technical development for thecompany. Areas of research include atherosclerosis, bile acid sequestrants, polymer synthesis andchemistry, phosphate binders for renal disease, gastrointestinal diseases, nutrition, obesity, diabetes, and cancer chemoprevention.

Through his research, Dr. Day has patented many inventions relating to the treatment of atherosclerosis, reducing serum cholesterol, treatment of irritable bowel syndrome, anti-flatulent compositions and antacids. He has developed dozens of products for treatments such as cancer chemoprevention, weight loss, reducing cholesterol, stroke and heart attack prevention, irritable bowel syndrome, memory enhancers and much more. He has written multiple books and continues his research today.

Dr. Day’s other areas of interest include nutritional pharmacology, Alzheimer’s disease, epilepsy, end stage renal disease, improved formulations for old drugs, 505 (b)(2) pathways for new prescription drug products, and functional and medical foods.